Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma

Overview of attention for article published in Frontiers in immunology, January 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 37,966 followers.

RT @sesiegler: @BiotechRadar NCI's GPC3 CAR has been licensed to Lentigen (i.e., @miltenyibiotec). See also: https://t.co/XuZsoz5P61 https:…

RT @FrontImmunol: Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma:… http…

RT @FrontImmunol: Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma:… http…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.